A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread

Phase 1 Dose Escalation Study of LY2334737 Using 2 Dosing Regimens in Patients With Advanced and/or Metastatic Solid Tumors

The purpose of this study is to evaluate two different dosing regimens of LY2334737 in participants with cancer that is advanced and/or has spread to other parts of the body. Information about side effects will be collected.

This study will consist of a Dose Escalation Phase (Arms A and B) followed by a Dose Confirmation Phase.

Inclusion Criteria:

• Diagnosis of advanced and/or metastatic cancer (including lymphoma) for which no treatment of higher priority exists
• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
• Estimated life expectancy of more than 12 weeks
• Have discontinued all previous therapies for cancer for at least 30 days (6 weeks for mitomycin-C or nitrosoureas) and recovered from acute effects of therapy
• Have discontinued radiotherapy more than one week before enrolling in the study and have recovered from the acute effects of therapy
• Have adequate organ function
• Follow your doctor's directions and live close enough to the study site so you can continue to go to the clinic for follow-up
• Are willing and able to swallow capsules and follow study procedures
• Have given written informed consent prior to any study-specific procedures
• Males and females with reproductive potential should use medically approved contraceptive precautions during the study and for 6 months following the last dose of study drug
• Females with child-bearing potential must have had a negative urine or serum pregnancy test 7 days prior to the first dose of study drug

Exclusion Criteria:

• Have gastrointestinal diseases or prior surgery that may interfere with the absorption of medication taken by mouth
• Females who are pregnant or lactating
• Symptomatic central nervous system malignancy or metastasis
• Known positive test results in human immunodeficiency virus (HIV), hepatitis B surface antigen (HBSAg), or hepatitis C antibodies (HCAb)
• Liver cirrhosis or chronic hepatitis
• Acute or chronic leukemia
• Are currently receiving treatment with valproic acid (VPA) and its derivatives, or if you have a history of intolerance to VPA
• Known hypersensitivity to gemcitabine